About this time a farmer buddy gave me some aronia berry juice and told me to drink it daily. I did. It’s high in antioxidants and anti-inflammatories. By the time we arrived at the U of I, the red ...

Squamous Cell Carcinoma Treatment. Skin Cancer Foundation. January 2022. Squamous Cell Carcinoma of the Skin: Diagnosis and Treatment. Mayo Clinic. May 13, 2021. Treatment for Squamous Cell Carcinoma.

Basal cell carcinoma is the most common type of cancer. If you’ve been diagnosed with basal cell carcinoma (BCC), you have plenty of company. Basal cell carcinoma is the most common type of skin ...

What looks like a sore on this woman’s scalp turned out to be squamous cell carcinoma. A non-healing pimple. The red-pink spot on this man’s nose is skin cancer. In darker skin tones, this type of ...

Traws Pharma published promising data on rigosertib for treating RDEB-associated SCC, showing an 80% response rate in clinical trials. The company is actively seeking development and ...

Scalp folliculitis is a skin condition involving inflammation of the hair follicles. Causes of this inflammation may include ingrown hairs, infection, and medication side effects. In this article ...

Cindy Perettie, executive vice president of Gilead's Kite cell therapy unit, said she is encouraged by the 62% response. "What we didn't see that we wanted to in a majority of the patients was ...

Regeneron Pharmaceuticals announced promising results from the Phase 3 C-POST trial of Libtayo (cemiplimab), a PD-1 inhibitor for patients with high-risk cutaneous squamous cell carcinoma (CSCC ...

In a phase 3, randomized trial, we enrolled patients with local or regional cutaneous squamous-cell carcinoma, after surgical resection and postoperative radiotherapy, at high risk for recurrence ...

A healthy 60-year-old man presented with a recurrent lesion on his left third finger after surgical treatment 7 years previously (Figure 1). A biopsy reveals squamous cell carcinoma (SCC) in situ ...

The results showed that Libtayo reduced the risk of squamous cell carcinoma recurrence or death by 68% compared with placebo over a 24-month period. Among the 209 patients randomly assigned to be ...